Key Metrics of Cellectis S.A.
Revenue$73.9M▲ 0.0% YoYFY 2020
Operating income−$85.4M▲ 0.0% YoY
Net profit−$97.5M▲ 0.0% YoY
Shareholders' equity$309M
Market cap$98.0MCLLS · $0.98
Competitors10identified
About Cellectis S.A.
Sectors
Company details
- Founded
- 2015
- Listed
- Nasdaq: CLLS (since 2015)
Operational Areas of Cellectis S.A.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameCellectis S.A.
TickerCLLS
ExchangeNasdaq
CountryFrance
SEC CIK0001627281
Listed since2015
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
CLLS · Nasdaq · SEC CIK 0001627281
Last price · 24 Oct 2026
$0.98
+0.67%
Market cap$98.0M
P/E—On FY 2020 diluted EPS
Volume129,355
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOFranceListed 2015
CLLS share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Cellectis S.A.
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.